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ABSTRACT 
 
Objective – The primary objective was to determine the incidence of bleeding events post-
acute coronary syndrome (ACS) following hospital discharge. The secondary objective was to 
determine the prognostic impact of bleeding on mortality, major adverse cardiovascular events 
(MACE), myocardial re-infarction and re-hospitalisation in the post discharge setting. 
Design – A narrative systematic review 
Data source - Medline, Embase, Amed and Central (Cochrane) were searched up to August 
2018.  
Study selection -  For the primary objective, randomised controlled trials (RCT) and 
observational studies reporting on the incidence of bleeding post-hospital discharge were 
included. For the secondary objective, RCTs and observational studies that compared patients 
with bleeding versus those without bleeding post-hospital discharge vis-à-vis mortality, 
MACE, myocardial re-infarction and re-hospitalisation were included.  
Results - 53 studies (36 observational studies and 17 RCTs) with a combined cohort of 714,458 
participants for the primary objectives and 187,317 for the secondary objectives were included. 
Follow-up ranged from 1 month to just over 4 years. The incidence of bleeding within 12-
months post-hospital discharge ranged from 0.20 to 37.5 percent in observational studies and 
between 0.96 and 39.4 percent in RCTs. The majority of bleeds occurred in the initial 3 months 
after hospital discharge with bruising the most commonly reported event. Major bleeding 
increased the risk of mortality by nearly threefold in 2 studies. One study showed an increased 
risk of MACE (HR: 3.00 (95% CI 2.75, 3.27; p<0.0001)) with bleeding and another study 
showed a non-significant association with re-hospitalisation (HR: 1.20 (95% CI 0.95, 1.52; 
p=0.13)). 
Conclusion - Bleeding complications following ACS management are common and continue 
to occur in the longer term after hospital discharge. These bleeding complications may increase 
the risk of mortality and MACE, but greater evidence is needed to assess their long-term 
effects. 
 
Systematic review registration   PROSPERO CRD 42017062378 
 
 
Keywords: Post discharge; Outpatient; Bleeding; Haemorrhage; Acute coronary syndrome; 
Mortality; MACE; Re-hospitalisation. 
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Strengths and limitations of this study 
 
 This is the first systematic review that has examined the incidence and prognostic 
impacts of bleeding complications post-acute coronary syndrome within the 
outpatient setting. 
 
 The review combined evidence from observational studies and RCT’s involving a 
total of 714,458 participants for the primary objectives and 187,317 for the 
secondary objectives. 
 
 The studies included in the review were heterogeneous in regards to bleeding 
definition, the ACS presentation, demographic characteristics of the study 
participants, severity and type of bleeding examined, length of follow-up, 
discharged anti-platelet and anti-coagulant regimens, therefore we were unable to 
pool data quantitatively. 
 
 The findings in relation to MACE and re-hospitalisation should serve as hypothesis 
generating due to limited data.  
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INTRODUCTION 
 
The management of acute coronary syndrome (ACS) depends on the clinical 
presentation, with an overall aim of reducing myocardial ischaemia and adverse ischemic 
events.1 This goal is fundamentally achieved via therapy with a combination of anti-thrombotic 
and invasive strategies. Paradoxically, these management strategies whilst achieving the 
desired goal of reducing ischemic events, increases the risk of bleeding complications.2–4 In 
the clinical trial setting, the incidence of major bleeding is reported to be between 1% and 10% 
depending on the bleeding definition used,5–7 with observational studies reporting incidences 
of between 2.8%8 and 11%.9 However, the emphasis in the majority of these studies has been 
on major in-hospital or 30-day bleeding events (a composite of in-hospital and post discharge 
events), with little consideration for events in the longer term after hospital discharge. Post 
hospital discharge, ACS patients may remain on dual antiplatelet therapy for up to a year, and 
aspirin indefinitely, so their risk of bleeding complications persist in the longer term. 
     Major bleeding is an independent predictor of adverse outcomes, including 
mortality, recurrent MI, stroke and stent thrombosis in patients with ACS.5,10–13 The association 
between major in-hospital bleeding events and adverse outcomes (most notably mortality) 
appeared to be maintained regardless of the definition of bleeding used.5,10–12,14These adverse 
events do, however, appear to depend on the anatomic site of the bleed,15 and the site of 
bleeding may vary between the in-hospital and the post discharge settings. Whilst the nature of 
in-hospital bleeds and their association with adverse events has been well described, the timing, 
types and association of bleeding events that occur late after hospital discharge with clinical 
outcomes such as mortality is unclear.  
     To date, there has not been a systematic review of the incidence, types and 
prognostic impact of bleeding events post hospital discharge for ACS. The primary objective 
of this systematic review was therefore to determine the incidence, timing and types of post- 
hospital discharge bleeds within the adult post-ACS population. The secondary objective was 
to determine the association of post-discharge bleeds with mortality, major adverse 
cardiovascular events (MACE), re-hospitalization and re-infarction in the outpatient setting.
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METHODS 
 
Eligibility criteria 
There were two linked objectives for the systematic review. For the primary objective, 
we selected studies that reported on the incidence, timing and types of bleeding post-ACS post-
hospital discharge. For the secondary objective, we included studies that compared patients 
with versus those without bleeding post-ACS post-hospital discharge in relation to mortality, 
MACE, myocardial re-infarction and re-hospitalisation. We only included randomised 
controlled trials (RCTs) where bleeding events were reported as secondary or safety outcomes, 
and observational studies which were published in English. Studies where the intervention was 
coronary artery bypass graft surgery (CABG) or elective percutaneous coronary intervention 
(PCI) were excluded. We also excluded studies where the study population comprised patients 
with stable angina or other coronary artery disease. See Table 1 for detailed inclusion and 
exclusion criteria for the review. For studies using the same data source, only one was included 
in the review, based on: 1) quality, and then by 2) sample size, followed by 3) length of follow-
up, unless the studies reported on different outcomes.
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Table 1: Inclusion and exclusion criteria specific to primary and secondary objectives 
 
Primary objective 
Inclusion Criteria Exclusion Criteria 
 Participants aged 18 years and 
over 
 Cannot be ascertained whether bleed 
occurred in-hospital or post-discharge 
 Participants discharged with an 
ACS diagnosis (UA or STEMI or 
NSTEMI) at index hospitalisation 
 In-hospital bleeds only 
 Randomised controlled trial or 
Observational study 
 Incidence and 95% CI or number of 
bleeding events cannot be extracted or 
calculated 
 Bleeding occurred after hospital 
discharge 
 Study population combined patients 
with ACS and other coronary diseases 
such as stable angina 
 Any type of bleeding examined 
(such as gastrointestinal bleed) 
post hospital discharge for ACS. 
 Post-discharge bleeding after PCI, 
without specifying the clinical 
presentation for the PCI or whether the 
PCI was elective. 
 Incidence and associated 95% 
confidence interval can be 
extracted or calculated 
 Only reporting CABG related bleeds 
  Conference/study abstracts, editorials 
and reviews 
Secondary objective 
Inclusion Criteria Exclusion Criteria 
 Participants aged 18 years and 
over 
 Cannot be ascertained whether bleed 
occurred in-hospital or post-discharge 
 Participants discharged with an 
ACS diagnosis (UA or STEMI or 
NSTEMI) at index hospitalisation 
 In-hospital bleeds only 
 Randomised controlled trial or 
Observational study 
 Study population combined patients 
with ACS and other coronary diseases 
such as stable angina 
 Bleeding occurred after hospital 
discharge 
 Post-discharge bleeding after PCI, 
without specifying the clinical 
presentation for the PCI or whether the 
PCI was elective. 
 Evaluated outcome of or 
composite of mortality, MI, re-
hospitalisation, and MACE in 
bleed Vs no bleed cohorts 
 Only reporting CABG related bleeds 
  Conference/study abstracts, editorials 
and reviews 
STEMI: ST-Elevation Myocardial Infarction, NSTEMI: Non ST-Elevation Myocardial Infarction, UA: 
Unstable Angina, ACS: Acute Coronary Syndrome, PCI: Percutaneous Coronary Intervention, CI: Confidence 
Interval, CABG: Coronary Artery Bypass Graft, MI: Myocardial Infarction.
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Search strategy 
MEDLINE (HDAS; 1946 – Aug 2018), EMBASE (Ovid SP; 1974 – Aug 2018), 
AMED (Ovid SP; 1985 – Aug 2018) and CENTRAL (Cochrane central register of controlled 
trials) were searched up to August 2018 using a search strategy which combined keywords and 
related database specific subject headings for both primary and secondary objectives (see 
supplementary Table 1 for the full search strategy used on the Embase database). The Journal 
of the American College of Cardiology (JACC), the European Heart Journal (EHJ), Heart, and 
Circulation were electronically searched for relevant articles and grey literature. The 
bibliographies of included studies and relevant review articles identified from each database 
were scrutinised for additional relevant articles. Citation tracking of included studies via Web 
of Science was carried out to retrieve additional relevant articles. 
 
Study selection 
The titles of all identified articles were screened and those which were obviously 
irrelevant were eliminated at this stage. The abstracts of the remaining articles were screened 
independently by NI and JP. Discordances were resolved by consensus between NI, JP and 
MAM. The full texts of the remaining articles were then screened by NI, with JP also screening 
1 in 10.  
 
Data extraction 
We extracted study characteristics including study design, setting, length of follow-up, 
in-hospital interventions, participant characteristics, discharged therapy and comorbidities. The 
outcomes of incidence of post-discharge bleeding and associated 95% confidence intervals, 
time of bleed, location/type of bleed, and the adjusted and unadjusted associations of bleeding 
with mortality, MACE, re-infarction and re-hospitalisation were extracted from individual 
studies onto a pre-piloted and formatted spreadsheet. In studies where incidence and associated 
95% confidence intervals were not reported but relevant data was available, incidence per 100 
persons at risk were calculated (i.e. essentially as a proportion). For studies that combined in-
hospital and post discharge bleeds, and episodes of bleeds were stratified by time (for instance 
at 30 days, 6 months, 12 months), bleeds that occurred within the initial 30 days were 
considered to be in-hospital bleeds (decided by consensus of NI, KJP, MAM, and UTK) and 
therefore removed from the numerator and denominator. Authors of original studies were 
contacted where necessary data was missing or to confirm methodological aspects or other 
characteristics of the study.  
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Quality Assessment 
Observational studies and post hoc observational analyses of RCTs were appraised by 
the Newcastle Ottawa Scale (NOS) for assessing risk of bias in non-randomised studies.16 The 
NOS quality assessment scale contains eight items partitioned into three categories of selection, 
comparability and outcome. A maximum of one star is allocated to a high quality study for 
each item under selection and outcome and a maximum of two stars under comparability, 
giving an overall maximum of nine stars. We considered studies with an overall number of 
stars greater than or equal to six stars as high quality studies.17Randomised controlled trials 
were appraised by the Scottish Intercollegiate Guideline Network (SIGN) quality assessment 
tool.18 Each study was categorised as high quality, acceptable quality or low quality based on 
the standard criteria for this tool. Quality assessment was based on the primary objective of 
each study as incidence of bleeding was typically reported as safety or secondary outcome 
measure.  
 
Data Synthesis 
A narrative synthesis approach was applied due to heterogeneity in relation to length of 
follow-up, ACS presentation, definition of bleeding used, type of bleeding examined, severity 
of bleeding examined, geographical location and discharge therapy across studies.  For the 
primary objective, the narrative synthesis was carried out in stages. Initially, the incidence of 
bleeding overall was summarised separately for observational studies and RCTs. The incidence 
of bleeding was then stratified by ACS presentation (ST-Elevation Myocardial Infarction 
(STEMI), Non ST-Elevation Myocardial Infarction/Unstable Angina (NSTEMI/UA)) and 
discharge antithrombotic drug combinations and duration (single antiplatelet (SAPT), dual 
antiplatelet (DAPT) and receipt of oral anticoagulant) in studies that reported these. To assess 
the incidence of bleeding by time from hospital discharge, the incidence of bleeding was 
stratified by follow-up time within studies which looked at multiple time periods. Where 
studies allowed, the incidence of bleeding stratified by major, minor and nuisance bleeds (see 
supplementary Table 2 for definitions), and the incidence of different types of bleeding events 
were examined.  
We assessed the strength of evidence (SOE) for each secondary outcome following the 
Agency for Healthcare Research and Quality guideline.19For each secondary outcome, 
assessment was carried out by examining risk of bias, consistency, directness and precision 
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across studies that reported on this outcome, and a grade allocated as high, moderate, low or 
insufficient based on these assessments. 
 
Patient and Public Involvement 
Patients and members of the public did not have any role in the design, conduct, data 
synthesis or reporting of the study. 
 
RESULTS 
The search of Medline, Embase, Amed and Central (Cochrane) identified 37 studies,20–
56 4 studies were further identified from  electronic search of the Journal of American College 
of Cardiology database,3,57–59 2 from Web of Science citation index, 60,61  9 from bibliographic 
screening of included studies, 4,62–69 and finally, 1 from recommendation by an expert within 
the field.70 Overall, 53 studies (36 observational studies and 17 RCTs)  were included in the 
review with a combined cohort of 714,458 participants for the primary objectives and 187,317 
for the secondary objectives (see Figure 1). Of the 53 studies, 45 only reported on the primary 
outcomes, 3 only reported on the secondary outcomes and 5 reported on both primary and 
secondary outcomes.   
 
Characteristics of included studies 
The characteristics of included studies (for the primary objective) are summarised in 
Table 2 for observational studies and Table 3 for RCTs. Overall, 50 studies reported on the 
primary outcome, of which 68% (n = 34) were cohort studies and 32% (n = 16) were RCTs. 
The characteristics of included studies for the secondary objective are summarised in Table 4. 
Overall, 8 studies reported on the secondary outcomes, of which 7 were cohort studies and one 
was an RCT. 
 Length of follow up varied from 30 days29 to just over 4 years69 post-hospital 
discharge. The number of participants ranged from 193 to 187,386. The definition for bleeding 
used by each study in the review are provided in supplementary Table 2. Some studies (n = 23) 
did not report bleeding events based on recognised definitions (such as BARC). Of the included 
studies, 27 had specified the in-hospital ACS management strategy. In 26 of these studies, PCI 
was the baseline management strategy, and in one study the management strategy was a 
combination of PCI, angiography and medical therapy. 
 
Risk of bias assessment 
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Summaries of risk of bias of individual studies are provided in Tables 2, 3 and 4. 69% 
(n = 25) of the observational studies were at high risk of bias due to lack of reporting on 
presence/absence of outcome at start of study, attrition rate, and comparability of cohorts based 
on analysis (whether study adjusted for confounders or not). 31% (n = 11) were at low risk of 
bias. 2 RCTs were high risk, 4 were at an acceptable risk of bias and 2 were low risk. The main 
reasons for low quality in RCTs were inadequate reporting on randomisation, concealment, 
blinding, adequacy and reliability of outcome measurements. For studies which were post hoc 
observational analysis of RCTs, five were high risk and four were at low risk of bias. 
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Table 2: Summary of observational studies included in the review by length of follow-up, bleeding definition used and in-hospital management strategy 
Primary 
Author 
Location Setting Study Design 
Length of 
Follow-up 
Bleeding Criteria 
In-hospital 
management 
strategy 
N 
Participants 
with Bleed (n) 
Crude Incidence 
of Bleeding per 
100 persons and 
95% CI 
Quality 
Score 
Cuisset et al 
200929 
France 
In-
patient 
Prospective 
cohort 
1 month TIMI major/minor PCI 597 16 2.68 (1.66, 4.31) * 2 
Braun et al 
201426 
Sweden Registry 
Retrospective 
cohort 
3 months BARC 2-5 PCI 263 26 9.89 (6.84, 14.1) * 5 
Amin et al 
201621 
US Registry 
Retrospective 
cohort 
6 Months BARC 1-5 PCI 9290 2246 24.2 (23.3, 25.1) * 5 
Amin et al 
201320 
US Registry 
Retrospective 
cohort 
12 months BARC 1 PCI 3560 1335 37.5 (35.9, 39.1) * 4 
Lattuca et al 
201636 
France 
In-
patient 
Prospective 
Cohort 
12 Months BARC 1-3 PCI 369 132 35.8 (31.1, 40.8) * 5 
Bacquelin et al 
201522 
France Registry 
Prospective 
cohort 
12 months BARC 2-5 PCI 1006 79 7.85 (6.35, 9.68) * 5 
Palmerini et al 
201459 
Multi-
centre 
Unclear 
Prospective 
cohort 
12 months BARC (any) PCI 1053 41 3.91 (2.89, 5.26) * 5 
Kassaian et al 
201533 
Iran Registry 
Prospective 
cohort 
12 months 
GUSTO mild, moderate, 
severe. 
NR 1640 23 1.40 (0.94, 2.10) * 4 
Yetgin et al 
201854  
Netherland Registry Cohort 12 months TIMI major  PCI 2443 23 0.94 (0.63, 1.41) * 5 
Fosbol et al 
201230 
US Registry 
Prospective 
cohort 
12 months 
Bleed leading to 
hospitalisation 
NR 7619 928 12.2 (11.5, 12.9) * 6 
Tsai et al 
201071 
Taiwan Registry 
Retrospective 
cohort 
12 months Gastrointestinal bleed NR 3580 273 7.63 (6.80, 8.54) * 5 
Garay et al 
201670  
Spain Registry 
Retrospective 
cohort 
12 months 
 Bleed leading to 
hospitalization, transfusion, 
or suspension of 
antithrombotics 
NR 1375 69 5.02 (3.98, 6.30) * 3 
Garay et al 
201855  
Multi-
centre 
Registry Cohort 12 months 
 Intracranial bleeding or 
bleed leading to 
hospitalisation or 
transfusion 
PCI 15401 489 3.18 (2.91, 3.46) * 5 
Effron et al 
201850  
US Registry 
Retrospective 
cohort 
12 months 
Bleed leading to 
hospitalisation or 
transfusion 
PCI 15788 492 3.12 (2.86, 3.40) * 4 
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Brinkert et al 
201747 
Canada Registry  Cohort 12 months 
Hospitalization with major 
bleeding 
PCI, 
angiography, 
medically 
22312 588 2.72 (2.51, 2.94) * 5 
Ko et al 201068 Canada Registry Cohort 12 months 
Bleed leading to 
hospitalisation 
PCI 8,672 230 2.65 (2.33, 3.01) * 6 
Boggon et al 
201125 
UK Registry 
Retrospective 
cohort 
12 months 
Any bleeding in patient 
GPRD or HES record 
NR 7543 NR 11.4 (10.4, 12.6) † 5 
Carrero et al 
201628 
Sweden Registry 
Prospective 
cohort 
12 months Major bleed NR 36001 333 0.92 (0.83, 1.03) * 7 
Graipe et al 
201531 
Sweden Registry 
Prospective 
cohort 
12 months Intracranial bleed NR 187,386 590 0.32 (0.30, 0.34) 6 
Wang et al 
201544 
US Registry cohort 12 months Haemorrhagic stroke NR 169,863 335 0.20 (0.18, 0.22) 5 
Barra et al 
201323 
Portugal 
In-
patient 
Prospective 
cohort 
13.4 
months 
(Mean) 
TIMI/GUSTO major 
criteria 
NR 852 60 7.04 (5.51, 8.96) * 3 
Sra et al 
201641 
Canada 
In-
patient 
Prospective 
cohort 
15 months BARC 1-5 PCI 2034 440 21.6 (19.9, 23.5) * 5 
Caneiro et al 
201848 
Spain Registry Cohort 
455 days 
(Median) 
BARC 2 - 3 PCI 4229 500 11.8 (10.9, 12.8) * 6 
Sorensen et al 
200940 
Denmark Registry 
Prospective 
cohort 
476.5 days 
(Mean) 
Fatal and non-fatal bleed  PCI 40812 1967 4.82 (4.62, 5.03) * 5 
Raposeiras et 
al 201852 
Multi-
centre 
Registry Cohort 
17.2 
months 
(Mean) 
BARC 3 or 5 PCI 4310 66 1.53 (1.21, 1.94) * 6 
Cuschieri et al 
201461 
US Registry 
Retrospective 
cohort 
1.7 years 
(Mean) 
Gastrointestinal bleed NR 3218 107 3.33 (2.76, 4.00) * 4 
Wong et al 
200645 
UK 
In-
patient 
Retrospective 
cohort 
21 months 
CURE major/life 
threatening 
NR 224 15 6.70 (4.10, 10.8) * 4 
Buresly et al 
200562 
Canada Registry Cohort 
654 days 
(Mean) 
Bleed leading to 
hospitalisation 
NR 21443 1428 6.66 (6.33, 7.00) * 3 
Voss et al 
201643 
New 
Zealand 
Registry cohort 
1.94 years 
(Mean) 
Other NR 3666 206 5.88 (5.15, 6.71) * 4 
Brener et al 
201657 
US and 
Germany 
Registry 
Prospective 
cohort 
24 months 
 TIMI, GUSTO and 
ACUITY Major bleed 
PCI 8582 430 5.17 (4.71, 5.66) * 5 
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Erta et al 
201851 
Turkey Registry Cohort 24 months 
Physician-confirmed 
bleeding event 
NR 1010 21 2.08 (1.36, 3.16) * 4 
Blin et al 
201746 
France Registry  Cohort 3 years 
Hospitalization with 
bleeding  
NR 1585 49 3.09 (2.35, 4.06) * 5 
Chamberlain 
et al 201627 
US Registry Cohort 4.3 years Other NR 1159 312 26.9 (24.5, 29.6) * 6 
Kazi et al 
201569 
US Registry 
Retrospective 
cohort 
4.42 years 
(Mean) 
Major spontaneous 
bleeding 
PCI 22527 368 1.63 (1.48, 1.81) * 5 
*Incidence and associated 95% CI calculated from data within study, †Incidence and associated 95% CI reported within study per 100 persons years, CI: Confidence Interval, NR; not reported,  
BARC; bleeding academic research consortium, GUSTO; global use of strategies to open occluded arteries, TIMI; thrombolysis in myocardial infarction, ACUITY; acute catheterisation and 
urgent intervention triage strategy, CURE; clopidogrel in unstable angina to prevent recurrent events, GPRD; general practice research database, HES; hospital episodes statistics, AMI; acute 
myocardial infarction, SD; standard deviation, Q1; lower quartile, Q3; upper quartile. 
 
 
 14 
Table 3: Summary of randomised controlled trials included in the review by length of follow-up, bleeding definition used and in-hospital management strategy 
Primary 
Author 
Location Trial Study Design 
Length of 
Follow-up 
Bleeding 
Criteria 
In-hospital 
management 
strategy 
N 
Participants 
with Bleed 
Crude Incidence of 
Bleeding per 100 
persons and 95% CI 
Quality 
Score 
Yusuf et al 
200656 
Multi-
centre 
OASIS - 5 
Randomised 
controlled trial 
6 months OASIS-5 major NR 20078 357 1.84 (1.66, 2.03) * High  
Jolly et al 
20094 
Multi-
centre 
CURE 
Post hoc 
analysis of RCT 
8 months CURE major PCI 2658 28 1.07 (0.74, 1.54) * 6† 
Khan et al 
201534 
Multi-
centre 
APPRAISE-2 
Post hoc 
analysis of RCT 
240 days 
(Median) 
Any bleeding 
event 
NR 7392 506 7.32 (6.73, 7.96) * 7† 
Carraba et al 
201663 
Italy BLESS 
Randomised 
controlled trial 
12 months BARC 1-3 PCI 193 76 39.4 (32.8, 46.4) * Acceptable  
Cuisset et al 
201749 
France TOPIC 
Randomised 
controlled trial 
12 months BARC ≥ 2 PCI 634 106 16.7 (14.0, 19.8) * low 
Han et al 
201532 
China BRIGHT 
Randomised 
controlled trial 
12 months BARC 1-5 PCI 2194 47 2.33 (1.76, 3.08) * Acceptable  
Savonitto et 
al 201242 
Italy 
Italian Elderly 
ACS 
Randomised 
controlled trial 
12 months 
BARC 2, 3a & 
3b 
NR 313 3 0.96 (0.33, 2.78) * Acceptable  
Mrdovic et 
al 201338 
Serbia RISK-PCI 
Post hoc 
analysis of RCT 
12 months 
TIMI 
major/minor 
PCI 2045 25 1.29 (0.87, 1.89) * 5† 
Atar et al 
200660 
Multi-
centre 
OPUS-TIMI 
16 
Post hoc 
analysis of RCT 
12 months 
Gastrointestinal 
bleed 
NR 10288 104 1.02 (0.84, 1.24) * 5† 
Kohli et al 
201435 
Multi-
centre 
TRITON-
TIMI 38 
Post hoc 
analysis of RCT 
15 months 
TIMI 
major/minor 
PCI 12674 407 3.23 (2.94, 3.56) * 7† 
Mahaffey et 
al 201337 
Multi-
centre 
TRACER 
Post hoc 
analysis of RCT 
502 days 
(Median) 
TIMI 
major/minor 
NR 11368 236 2.12 (1.87, 2.41) * 6† 
Yeh et al 
20153 
US DAPT 
Randomised 
controlled trial 
18 months BARC 2-5 PCI 3576 111 3.10 (2.58, 3.72) * Acceptable  
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Costa et al 
201566 
Italy PRODIGY 
Post hoc 
analysis of RCT 
24 months BARC 2-5 PCI 1465 82 5.60 (4.53, 6.89) * 5† 
Bonaca et al 
201567 
Multi-
centre 
PEGASUS-
TIMI 54 
Randomised 
controlled trial 
33 months TIMI major NR 21162 435 2.08 (1.89, 2.28) * High  
Nikolsky et 
al 201558 
Multi-
centre 
HORIZON-
AMI 
Post hoc 
analysis of RCT 
3 years 
HORIZON 
major 
PCI 3602 63 2.15 (1.68, 2.74) * 5† 
Bergen et al 
199424 
Netherland ASPECT 
Randomised 
controlled trial 
37 months Major bleed NR 3404 99 2.91 (2.39, 3.53) * Low  
*Incidence and associated 95% CI calculated from data within study, † Quality assessed by Newcastle Ottawa Scale, CI: Confidence Interval, BARC; bleeding academic research consortium, 
GUSTO; global use of strategies to open occluded arteries, TIMI; thrombolysis in myocardial infarction, CURE; clopidogrel in unstable angina to prevent recurrent events, HORIZON; 
harmonizing outcomes with revascularisation and stents, RCT; randomised controlled trial, GI; gastrointestinal, Q1; lower quartile, Q3; upper quartile.OASIS-5; the fifth organization to assess 
strategies in acute ischemic syndromes, SIGN; Scottish intercollegiate guideline network, APPRAISE-2; Apixaban for prevention of acute ischemic events,  BLESS; Bleeding events and 
maintenance dose of prasugrel, TOPIC; Timing of platelet inhibition after acute coronary syndrome, BRIGHT; Bivalirudin in acute myocardial infarction vs heparin and glycoprotein inhibitor 
plus heparin, RISK-PCI; Risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention, TRACER; Thrombin receptor antagonist for 
clinical event reduction in acute coronary syndrome, OPUS-TIMI 16; Orbofiban in patients with unstable coronary syndrome-thrombolysis in myocardial infarction 16, TRITON-TIMI 38; 
Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38, DAPT; Dual antiplatelet therapy study, 
PRODIGY; Prolonging dual antiplatelet treatment after grading stent induced intimal hyperplasia, PEGASUS-TIMI 54; Prevention of cardiovascular events in patients with prior heart attack 
using ticagrelor compared to placebo on a background of aspirin thrombolysis in myocardial infarction 54, HORIZON-AMI; Harmonizing outcomes with revascularisation and stents in acute 
myocardial infarction, ASPECT; Anticoagulants in the secondary prevention of events in coronary thrombosis. 
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Incidence of bleeding 
In a cohort of 611,412 participants, 14,217 (2.3%) episodes of bleeds were reported in 
thirty-four observational studies and 2,685 (2.6%) episodes in a cohort of 103,046 participants 
in sixteen RCTs (714,458 participants overall). A summary of the incidence from each study 
is presented by length of follow-up, bleeding definition used and in-hospital management 
strategy in Table 2 for observational studies and Table 3 for RCTs. The overall incidence of 
bleeding within 12 months post hospital discharge varied from 0.244 to 37.520 percent in 
observational studies, and between 0.9642 to 39.463 percent in RCTs.  
The incidence of bleeding stratified by ACS presentation (STEMI, NSTEMI/UA) and 
discharge antithrombotic drug combinations and duration (SAPT, DAPT and receipt of oral 
anticoagulant)  are summarised by length of follow-up and the bleeding definition used in 
supplementary Tables 3, 4, and 5. Among those discharged on DAPT with aspirin and a 
thienopyridine, the incidence of bleeding within the first 12 months based on BARC criteria 
ranged from 3.91 to 38.8 (see supplementary Table 4) in observational studies, and between 
0.96 to 47.4 percent in RCTs (see supplementary Table 5). 
Eight observational studies23,36,45,47,51,54,59,70  and two RCTs56,58 comprising 53,318 
participants reported bleeding episodes at different time points during follow-up. In these 
studies, around one-half of bleeds that occurred in the first year post hospital discharge for 
ACS happened in the initial 1 – 3 months (Figure 2). 
The incidence of major bleeding events in observational studies (based on BARC 3 – 
5) within the first 12 months of hospital discharge was around 1.29 – 3.25 percent. The 
incidence of minor bleeding events (based on BARC 2) and nuisance bleeds (based on BARC 
1) within the same period were around 6.56 – 10.6, and 21.9 – 37.5 percent respectively (see 
supplementary Table 6 and Figure S1). Generally, bruising (defined as skin haematoma, 
ecchymoses, petechiae) were the most commonly reported types of bleeding events post 
hospital discharge (range: 1.49 to 22.5 percent within 12 months) followed by gastrointestinal 
bleeds (range: 0.25 to 7.63 percent within 12 months; see supplementary Table 7 and Figure 
S2). 
 
Bleeding and risk of mortality 
There was consistent reporting of an association between post discharge bleeding and 
all-cause mortality in five observational studies39,47,48,57,64 and one RCT53 (Table 4). Major 
bleeding was associated with nearly threefold increased risk of mortality in the first 12 months 
of hospital discharge in two studies (Table 4).47,64 Nuisance bleeding events defined as BARC 
 17 
1 were not associated with mortality, but there was an increased risk of mortality with BARC 
2 and 3 bleeds in one RCT,53 which increased with bleeding severity (Table 4). The SOE for 
the outcome of mortality was rated low (supplementary Table 8). 
 
Bleeding and risk of MACE, re-hospitalisation and re-infarction. 
The adjusted risk (HR) of MACE with bleeding (defined as bleeds leading to 
hospitalisation or death) was 3.00 (95% CI 2.75, 3.27 in 1 study (Table 4)).40 There was a 
statistically non-significant association between post discharge bleed (defined as BARC 1 
bleeds) and risk of re-hospitalisation (adj HR, 1.20 (95% CI 0.95, 1.52 in another study (Table 
4)).20 There were no studies examining the association between post discharge bleeding and 
subsequent risk of re-infarction. The SOE for the outcomes of MACE and re-hospitalisation 
were rated insufficient (supplementary Table 8). 
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Table 4:  Summaries of risk of mortality, MACE and re-hospitalisation from included studies by length of follow-up 
Primary 
Author 
Location Setting 
Length of 
follow-up 
Bleeding Criteria 
Adjusted/Unadjusted Outcomes Quality 
Score Mortality MACE Re-hospitalisation 
Lamberts et al 
201364 
Denmark Registry 12 months Fatal and non-fatal bleed Adj HR 2.79 (95% CI: 2.39, 3.26) NR NR 7 
Brinkert et al 
201747 
Canada Registry 12 months 
Hospitalisation with major 
bleeding 
Adj OR 2.97 (95% CI: 1.71, 5.15) NR NR 5 
Caneiro et al 
201848 
Spain Registry 
455 days 
(Median) 
BARC 2 - 3 Adj HR 5.1 (95% CI, 3.6, 7.7) NR NR 6 
Brener et al 
201657 
US and 
Germany 
Registry 24 months 
TIMI, GUSTO and 
ACUITY Major bleed 
Bleeds between 30-365 days; 
Unadj HR 4.61 (95% CI 1.70, 
12.49): NR NR 5 
Bleeds >365 days; Unadj HR 2.63 
(95% CI 0.86, 8.04) 
Olsen et al 
201539 
Denmark Registry 3.5 years 
Bleed leading to death or 
hospitalisation 
Adj HR 1.51 (95% CI: 1.28, 1.79) NR NR 6 
Valgimigli et al 
201753 
Multi-centre RCT Unclear BARC 1 - 3 
BARC 1: Adj HR 0.89 (95% CI: 
0.61, 1.31) 
NR NR 4† 
BARC 2: Adj HR 1.70 (95% CI: 
1.23, 2.36) 
BARC 3a: Adj HR 2.77 (95% CI: 
1.86, 4.12) 
BARC 3b: Adj HR 4.51 (95% CI: 
2.86, 7.10) 
BARC 3c: Adj HR 28.2 (95% CI: 
17.5, 45.7) 
Sorensen et al 
200940 
Denmark Registry 
476.5 days 
(Mean) 
Fatal and non-fatal bleed NR 
Adj HR 3.00 (95% 
CI: 2.75, 3.27) 
NR 5 
Amin et al 
201320 
US Registry 12 months BARC 1 NR NR 
Adj HR, 1.20 (95% CI 
0.95, 1.52) 
4 
Adj; adjusted, unadj; unadjusted, HR; hazard ratio, OR; odd ratio, NR; not reported, CI; confidence interval, MACE; Major Adverse Cardiovascular Event, BARC; bleeding academic research 
consortium, GUSTO; global use of strategies to open occluded arteries, TIMI; thrombolysis in myocardial infarction, ACUITY; acute catheterisation and urgent intervention triage strategy, †; 
quality assessed by Newcastle Ottawa Scale. 
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DISCUSSION 
Our systematic review is the first to study the incidence, timing, and types of post-
discharge bleeding complications, and their association with mortality, MACE, re-infarction 
and re-hospitalisation. 53 studies were included, comprising 36 observational studies and 17 
RCTs with a combined cohort of 714,458 participants for the primary objectives and 187,317 
for the secondary objectives. We report that bleeding complications post ACS are common 
following hospital discharge, and vary by length of follow-up, severity, type and the definition 
of bleeding used. We report that the incidence of bleeding was highest in the initial three 
months after hospital discharge for ACS, with bleeding events continuing to occur even after 
1 year post discharge. The majority of post discharge bleeding events were nuisance bleeds 
such as ecchymosis and petechiae, with major bleeding events such as intracranial 
haemorrhage less common. Whilst there was substantial heterogeneity between studies, we 
report that up to one third of patients discharged on DAPT will experience bleeding 
complications, and around 1.3 – 3.3 percent of patients will experience a major bleed in the 
first 12 months after hospital discharge.  
Our review shows that major bleeding may increase the risk of mortality by nearly 
threefold in the first 12 months after hospital discharge, but the strength of the evidence was 
weak. We identified very limited data on whether post-discharge bleeding was associated with 
MACE and re-hospitalisation. Although there was an indication of an association with MACE 
in one study40 and re-hospitalisation in another,20 the latter association did not reach statistical 
significance.  
 
Clinical Implications 
Although current guidelines72–74 have recommended dual therapy with aspirin and a 
thienopyridine for up to 12 months and triple therapy in the presence of comorbid conditions 
such as atrial fibrillation for shorter periods, it was evident from our study that these 
maintenance therapies are accompanied by bleeding complications which predominantly occur 
post hospital discharge. Consideration must therefore be given to ways of minimising these 
bleeding complications, such as by encouraging clinicians to use  risk scoring algorithms such 
as DAPT,75 precise-DAPT,76 BleeMACS score77 (for ACS patients treated with PCI) or 
TRILOGY-ACS bleeding risk model78 (for NSTEMI/UA patients managed medically) to 
identify patients at higher risk of these bleeding complications, such that maintenance oral 
antithrombotics or newer oral anticoagulants that have more favourable safety profile than 
warfarin can be tailored to fit each patient’s risk profile. However, it must be borne in mind 
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that many of these risk algorithms were developed in the clinical trial setting, and have not yet 
been validated in unselected cohorts. Aspirin regardless of dose increases the risk of 
gastrointestinal bleeds.79,80 In high risk patients such as those with previous history of these 
types of bleeds, concomitant use of a proton pump inhibitor as advocated by the ESC guidelines 
will reduce the future risk of these bleeds.81  
 
Research implications 
The majority of studies in this review were not primarily designed to investigate the 
incidence of bleeding complications. This meant that incidences could only be reported here 
as per 100 persons, i.e. essentially as a proportion, rather than per 100 persons years at risk. 
This underscores the need to examine the incidence of these bleeding events using high quality 
observational studies that are more reflective of the real-world populations encountered in 
clinical practice. The incidence of post-discharge bleeding complications may vary by type of 
bleed, patient demographics and discharge pharmacotherapy. Future studies should explore 
factors associated with post-discharge bleeding complications so that risk stratification tools 
that are more representative of the unselected cohorts encountered in clinical practice (often 
ignored in RCTs)  can be developed to identify individuals at high risk of bleeding post hospital 
discharge, as most contemporary bleeding risk scores predict in-hospital bleeding events.82–84 
 We also report that bleeding complications post hospital discharge may be associated 
with subsequent risk of mortality, although evidence from the literature was limited. The risks 
of MACE and re-hospitalisation were only reported in two studies, and none of the studies in 
the review reported on re-infarction. Future research is required to quantify these associations, 
with particular emphasis on whether nuisance and minor bleeding events that are much more 
common post hospital discharge also have a prognostic impact. Finally, future research 
examining these associations should stratify by the timing of bleeding events in order to 
determine whether the prognostic impacts of these bleeding complications are more 
pronounced in the early phases of hospital discharge or are equally important in the longer term 
after hospital discharge.  
Limitations of the review 
This study has several potential limitations. First, the studies included in the review 
were too heterogeneous in regards to bleeding definition, ACS presentation, demographic 
characteristics of the study participants, severity and type of bleeding examined, length of 
follow-up, discharge anti-platelet and anti-coagulant regimens to pool data to obtain an overall 
incidence and mortality figures. Second, the duration and dosage of discharge antithrombotic 
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therapy as well as ACS management strategies were not specified in the majority of studies 
(due to selective reporting), as such we were unable to adequately assess the impact of these 
factors on the incidence of bleeding. In the majority of studies, episodes of bleeds were 
extracted to calculate incidence figures. In most of these studies, there was lack of clarity on 
whether patients were included in the numerator more than once if they had multiple episodes 
of bleeds. However, since bleeding complications are rare events5,7,85 and having more than 
one episode of bleeding is even rarer, it is unlikely that this would have affected the overall 
incidence. Similarly, for some studies where episodes of bleeds were reported at different time 
intervals and the number of people at risk within each time interval were not reported, incidence 
figures were estimated based on the assumption that there was no attrition, hence these figures 
may have been underestimated. 
 
Conclusions 
In this systematic review of 53 studies, bleeding complications post hospital discharge 
for ACS were found to be common, with bruising the most common. These bleeding 
complications vary by severity, anatomic source and type of discharge antithrombotic therapy, 
and whilst most common immediately post-discharge, these bleeds continue to occur in the 
longer term. There are limited data around the longer term outcomes of patients that sustain 
bleeding events post hospital discharge for ACS. Further work is required to define the nature, 
frequency and prognostic impact of such bleeding events, using formal bleeding definitions. 
Real world risk stratification tools will need to be developed that specifically predict the risk 
of bleeding complications post discharge to identify high-risk individuals for a more patient-
centred approach in managing optimal pharmacotherapy and care. 
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What is already known on this topic 
 
 Oral antithrombotics are effective in reducing ischaemic events albeit at the expense 
of increased risk of bleeding. 
 
 These bleeding complications continue to occur even after hospital discharge post-
ACS. 
 
 The rate and prognostic impact of bleeding events that occur in the in-hospital settings 
has been well established whereas the rate of bleeds that occur in the longer term after 
hospital discharge and their prognostic impacts are unclear. 
 
What this study adds 
 
 Bleeds post hospital discharge for ACS are common, especially within the first 3 
months. 
 
 These bleeds vary by severity, anatomic source and discharge antithrombotic therapy. 
 
 These longer term bleeding complications may increase the risk of mortality, MACE 
and rehospitalisation. 
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Figure 1: Prisma flow chart depicting steps involved in selecting or rejecting studies for 
inclusion in the review. 
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Figure 2: Cumulative incidence of bleeding as reported within individual studies at different time points (incidence expressed as proportion per 100 persons) 
 
